At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 215 enrolled
Drug / intervention
silodosindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Placebo-Controlled Phase 2 Study of Silodosin 8 mg Daily for the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia
In Brief
A Phase 2 clinical trial evaluating silodosin for Nocturia and Prostatic Hyperplasia. Completed, enrolled 215 participants across 27 sites.
Detailed Summary
Silodosin is compared to placebo to determine if it is safe and effective for the treatment of nighttime urination (nocturia) in men with BPH
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNocturia, Prostatic Hyperplasia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2008
Enrollment StartJan 2009
Primary CompletionOct 2009
TodayJul 2026
First PostedNov 19, 2008
Enrollment StartJan 1, 2009
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.6 years ago
Interventions
silodosindrug
α1-adrenergic antagonist